Krystal Biotech receives permanent J-code for VYJUVEK

Krystal Biotech announced that the U.S. Centers for Medicare & Medicaid Services, CMS, has assigned a permanent and product-specific J-code for VYJUVEK, the first U.S. Food and Drug Administration-approved treatment for dystrophic epidermolysis bullosa, DEB. The J-code for VYJUVEK became effective on January 1, 2024. “The permanent J-code will help ensure efficient and accurate reimbursement of VYJUVEK and further enable us to bring this important treatment to DEB patients in need,” said Krish Krishnan, Chairman & CEO at Krystal Biotech